Details
Category: Volume 07 Issue 08 August 2019
Hits: 922

Title: Case Study of Infiltrating Carcinoma of the Breast in Correlation with the Incidence of the Estrogen Receptor [ER], Progesteron Receptor [PR] and HER2nue Status

Authors: Dr Nandini Venkatesh, Dr Ramya Jayaram, Dr Vishnukumar Venkatesan

 DOI: https://dx.doi.org/10.18535/jmscr/v7i8.118

Abstract

Introduction

Globally breast carcinoma is the leading cause of cancer related death in women worldwide. Despite  the  high  incidence  rates,  in  Western countries, 89% of women diagnosed  with  breast cancer  are still  alive  5 years  after  their  diagnosis,  which  is due  to early  detection  and  treatment . The UK and USA have one of the highest  incidence  rates  worldwide  (together with  the rest  of North  America  and Australia/ NewZealand), making these countries a priority for breast cancer awareness. Estrogen and progesterone and HER-2 protein play a central role in regulating growth kinetics of breast tissue and are powerful predictive markers. now the immunohistochemistry testing for hormonal receptors status is mandatory in breast cancer.

In urban India breast cancer accounts for about 25% to 33% of all cancers in women. In women, incidence rates of breast cancer rise sharply with age until ages 45 to50, when the rise becomes less steep. This change in slope probably reflects the impact of hormonal change (menopause) that occurs about this time. Over 50% breast cancer patients in India present in stages 3 and 4, which will definitely impact their survival and the overall 5 year survival for breast cancer patients in India doesn't appear to be even 60% presently.

References

  1. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. 1998;3:95-103.
  2. Payne SJ, Bowen RL, Jones JL, Wells CA . Predictive markers in breast cancer the present. Histopathology.2008;52:82-90.
  3. Ferlay J, Bray F, Pisani P. and Parkin DM . GEOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, version 2.0. IARC Press, Eyon, 2004.
  4. Tewari M, Krishnamurthy A, Shukla HS . Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol. 2008;7:301-311.
  5. Mohammed HR, Eakatua DJ, Haus E, YasminehWJ .Estrogen and progesterone receptors in human breast cancer. Correlation with histological subtype and degree of differentiation in University of Minnesota Cancer Cytopathology -CA: a Cancer Journal for Clinicians.2006; 58:1076-81.
  6. Breasted JH: The Edwin Smith Surgical Papyrus. Chicago: University of Chicago Press,. Classics of Medicine Eibrary, vol. III. 1930;405 .
  7. Celsus AC: De Medicina, Vol II. Eoeb Classical Eibrary Ed, Book V. Cambridge: Harvard University Press, 1935; p. 131.
  8. Beenken SW5 et al: History of the therapy of breast cancer, in Bland and Copeland (eds): The Breast: Comprehensive Management of Benign and Malignant Disorders. Philadelphia: Saunders. 2004; p 5.
  9. Moore C: On the influence of inadequate operations on the theory of cancer. R MedChirSoc. 1867; 1:244.
  10. Halsted WS: I. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg1894;20:497.
  11. Richard Sainsbury. The Breast, Bailey and Love Short Practice of Surgery 25th edition 2008; 50:827-47.
  12. Iglehart D J,Smith LB . The Breast ,Sabiston Text Book of Surgery 18th edition 2008; 7:861-96.
  13. Bland I K,Beenken WS ,Copeland E M.The Breast Schwartz Text Principles of Surgery 9th edition 2008; 15:453-94.
  14. Burstein HJ, Hams JR, Marrow M .Malignant Tumors of The Breast. Devita 8th edition 2008; 43.2: 1606-12.
  15. Mohla S, Sampson C C, Enterline J P .Estrogen and Progestrone Receptors in Breast Cancer in Black Americans ,Correlation of Receptor Data with Tumor Differentiation, Cancer Journal 1982; 50: p552-59.
  16. Eisenberg ALA, Koifman S..Hormone receptor Association with Prognostic Factor for Breast Cancer. Revista Brasileria de Cancerologia 2001 ;47:49-58.
  17. Almasri M N and Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan Breast Cancer Research:2005;7: 598-604.
  18. Azizun-Nisa1, Bhurgri Y, Raza F, Kayani N. Asian Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Pac J. Can Prev 2008 Oct-Dec;9(4):553-6.
  19. Faheem M1, Mahmood H, Khurram M, Qasim U, Irfan J. Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan. Ecancermedicalsciene 2012;6: 283. doi: 10.3332 / ecancer.2012.283. Epub 2012 Dec 11
  20. Hussein MR1, Abd-Elwahed SR, Abdulwahed AR.. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Cell Bio lint. 2008 Jun;32(6):698-707.
  21. Naqvi SQH, Jamal Q, Mahmood RK, Zaidi SMH, Abbas F. Significance of her 2 neu oncoprotein over expression on node positive invasive breast cancer. J. coll Physician Surg 2002.
  22. Fatima S1, Faridi N, Gill S. Breast cancer: steroid receptors and other prognostic indicators. J. Coll. Physicians surg Pak 2005 Apr;15(4):230-3.
  23. Lu X, Gu Y, Ding Y, Song W, Mao J, Tan J, Zhao H, Han X, Sun Y. Correlation of ER, PgR, HER-2/neu, p53, and VEGF with clinical characteristics and prognosis in Chinese women with invasive breast cancer. Breast Journal 008 May-Jun;14(3):308.

Corresponding Author

Dr Nandini Venkatesh